For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$129.31
Thesis
Gilead is anchored by a dominant HIV franchise led by Biktarvy, with lenacapavir extending the platform into long-acting twice-yearly treatment and PrEP. Oncology — Trodelvy and the cell therapy assets from Kite — is the second leg, intended to diversify the company away from HIV concentration.
The HIV cash flow is durable, and lenacapavir as PrEP is a potential category-redefining product; the oncology build remains the open execution question.
Catalysts
- Lenacapavir PrEP launch trajectory and access expansion
- Trodelvy label expansions in earlier-line breast cancer
- Cell therapy pipeline progress at Kite
- Capital returns and disciplined M&A given the cash flow profile
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jun 2OtherClinicalTrials.gov
Phase 3 trial NCT05568095 (domvanalimab + zimberelimab + chemo, upper GI cancer) sponsored by Arcus Biosciences updated to ACTIVE_NOT_RECRUITING status.
- May 20DealSEC
8-K filing (items 1.01,2.03,8.01,9.01) on material agreement and financial obligation.
- May 14Securities offeringSEC
Gilead Sciences filed SEC Form 424B5 prospectus supplement.
- May 7Financial resultsSEC
Gilead Sciences filed 8-K (items 2.02, 9.01) disclosing financial results.
- May 7Trial initiationClinicalTrials.gov
Kite (Gilead) Phase 3 trial NCT06413498 (anitocabtagene autoleucel vs SOC) in R/R multiple myeloma status updated to RECRUITING